2025
Utility of Candidate Genes From an Algorithm Designed to Predict Genetic Risk for Opioid Use Disorder
Davis C, Jinwala Z, Hatoum A, Toikumo S, Agrawal A, Rentsch C, Edenberg H, Baurley J, Hartwell E, Crist R, Gray J, Justice A, Gelernter J, Kember R, Kranzler H, Muralidhar S, Moser J, Deen J, Tsao P, Gaziano J, Hauser E, Kilbourne A, Matheny M, Oslin D, Churby L, Whitbourne S, Brewer J, Shayan S, Selva L, Pyarajan S, Cho K, DuVall S, Brophy M, Stephens B, Connor T, Argyres D, Assimes T, Hung A, Kranzler H, Aguayo S, Ahuja S, Alexander K, Androulakis X, Balasubramanian P, Ballas Z, Beckham J, Bhushan S, Boyko E, Cohen D, Dellitalia L, Faulk L, Fayad J, Fujii D, Gappy S, Gesek F, Greco J, Godschalk M, Gress T, Gupta S, Gutierrez S, Harley J, Hamner M, Hurley R, Iruvanti P, Jacono F, Jhala D, Kinlay S, Landry M, Liang P, Liangpunsakul S, Lichy J, Mahan C, Marrache R, Mastorides S, Mattocks K, Meyer P, Moorman J, Morgan T, Murdoch M, Norton J, Okusaga O, Oursler K, Poon S, Rauchman M, Servatius R, Sharma S, Smith R, Sriram P, Strollo P, Tandon N, Villareal G, Walsh J, Wells J, Whittle J, Whooley M, Wilson P, Xu J, Yeh S, Bast E, Dryden G, Hogan D, Joshi S, Lo T, Morales P, Naik E, Ong M, Petrakis I, Rai A, Yen A. Utility of Candidate Genes From an Algorithm Designed to Predict Genetic Risk for Opioid Use Disorder. JAMA Network Open 2025, 8: e2453913. PMID: 39786773, PMCID: PMC11718552, DOI: 10.1001/jamanetworkopen.2024.53913.Peer-Reviewed Original ResearchConceptsOpioid use disorder riskElectronic health record dataHealth record dataInternational Classification of DiseasesOpioid use disorderClassification of DiseasesGenetic variantsInternational ClassificationGenetic riskRecord dataRisk of opioid use disorderMillion Veteran ProgramOpioid use disorder diagnosisUse disorderCase-control studyVeteran ProgramMain OutcomesDiagnostic codesClinical careOpioid exposurePharmacy recordsLogistic regressionRisk allelesNagelkerke R2Clinically useful model
2024
GLP1R Gene Expression and Kidney Disease Progression
Triozzi J, Yu Z, Giri A, Chen H, Wilson O, Ferolito B, Ikizler T, Akwo E, Robinson-Cohen C, Gaziano J, Cho K, Phillips L, Tao R, Pereira A, Hung A, Muralidhar S, Moser J, Deen J, Tsao P, Gaziano J, Hauser E, Kilbourne A, Matheny M, Oslin D, Churby L, Whitbourne S, Brewer J, Shayan S, Selva L, Pyarajan S, Cho K, DuVall S, Brophy M, Stephens B, Connor T, Argyres D, Assimes T, Hung A, Kranzler H, Aguayo S, Ahuja S, Alexander K, Androulakis X, Balasubramanian P, Ballas Z, Beckham J, Bhushan S, Boyko E, Cohen D, Dellitalia L, Faulk L, Fayad J, Fujii D, Gappy S, Gesek F, Greco J, Godschalk M, Gress T, Gupta S, Gutierrez S, Harley J, Hamner M, Hurley R, Iruvanti P, Jacono F, Jhala D, Kinlay S, Landry M, Liang P, Liangpunsakul S, Lichy J, Mahan C, Marrache R, Mastorides S, Mattocks K, Meyer P, Moorman J, Morgan T, Murdoch M, Norton J, Okusaga O, Oursler K, Poon S, Rauchman M, Servatius R, Sharma S, Smith R, Sriram P, Strollo P, Tandon N, Villareal G, Walsh J, Wells J, Whittle J, Whooley M, Wilson P, Xu J, Yeh S, Bast E, Dryden G, Hogan D, Joshi S, Lo T, Morales P, Naik E, Ong M, Petrakis I, Rai A, Yen A. GLP1R Gene Expression and Kidney Disease Progression. JAMA Network Open 2024, 7: e2440286. PMID: 39453656, PMCID: PMC11581634, DOI: 10.1001/jamanetworkopen.2024.40286.Peer-Reviewed Original ResearchConceptsGenetic association studiesKidney disease progressionRisk of kidney disease progressionVeterans Affairs Million Veteran ProgramAssociation studiesGenetic risk scoreMillion Veteran ProgramGLP-1RAsDisease progressionIncident end-stage kidney diseaseBody mass indexGlycemic controlGene expressionVeteran ProgramObesity statusMain OutcomesUnadjusted modelsGlucagon-like peptide 1 receptor agonistsStudy participantsPeptide 1 receptor agonistsAbsence of diabetesMass indexMedian follow-upRisk scoreGenotype-Tissue Expression projectThe Management of Posttraumatic Stress Disorder and Acute Stress Disorder: Synopsis of the 2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline.
Schnurr P, Hamblen J, Wolf J, Coller R, Collie C, Fuller M, Holtzheimer P, Kelly U, Lang A, McGraw K, Morganstein J, Norman S, Papke K, Petrakis I, Riggs D, Sall J, Shiner B, Wiechers I, Kelber M. The Management of Posttraumatic Stress Disorder and Acute Stress Disorder: Synopsis of the 2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Annals Of Internal Medicine 2024, 177: 363-374. PMID: 38408360, DOI: 10.7326/m23-2757.Peer-Reviewed Original ResearchConceptsClinical practice guidelinesU.S. Department of Veterans AffairsDepartment of Veterans AffairsVeterans AffairsPosttraumatic stress disorderManagement of posttraumatic stress disorderAcute stress disorderExternal group of expertsPractice guidelinesDefense Clinical Practice GuidelinesStress disorderPatient-centered careIndividual health outcomesRevised CPGDepartment of Defense Clinical Practice GuidelinesVideo teleconferencingStrength of evidenceQuality of lifeCo-occurring conditionsHealth outcomesPatient perspectiveEvidence-basedPosttraumatic stress disorder treatmentSystematic searchCognitive processing therapy
2023
Developing Researchers with Expertise in Sex as a Biological Variable through SCORE Career Enhancement Core Center Programs
Zakiniaeiz Y, Peltier M, Mineur Y, Gueorguieva R, Picciotto M, Petrakis I, Cosgrove K, McKee S. Developing Researchers with Expertise in Sex as a Biological Variable through SCORE Career Enhancement Core Center Programs. Journal Of Women's Health 2023, 32: 852-857. PMID: 37585509, PMCID: PMC10457604, DOI: 10.1089/jwh.2023.0015.Peer-Reviewed Original Research
2017
Partnering with Psychiatry to Close the Education Gap: An Approach to the Addiction Epidemic
Tetrault JM, Petrakis IL. Partnering with Psychiatry to Close the Education Gap: An Approach to the Addiction Epidemic. Journal Of General Internal Medicine 2017, 32: 1387-1389. PMID: 28766126, PMCID: PMC5698217, DOI: 10.1007/s11606-017-4140-9.Peer-Reviewed Original Research
1999
NMDA Agonists and Antagonists as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric Disorders
Krystal J, D'Souza C, Petrakis I, Belger A, Berman R, Charney D, AbiSaab W, Madonick S. NMDA Agonists and Antagonists as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric Disorders. Harvard Review Of Psychiatry 1999, 7: 125-143. PMID: 10483932, DOI: 10.3109/hrp.7.3.125.Peer-Reviewed Original ResearchConceptsN-methyl-D-aspartate (NMDA) subclassChronic pain syndromePain syndromeGlutamatergic dysfunctionNMDA agonistClinical studiesMajor depressionNMDA antagonistsGlutamate receptorsCoagonist siteParkinson's diseaseHuman psychopharmacological studiesPartial agonistAlzheimer's diseaseNeuropsychiatric conditionsNeuropsychiatric disordersDiseasePsychopharmacological studiesAnxiety disordersHuntington's diseaseAgonistsAntagonistTherapeutic hypothesesDisordersAddiction disorders
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply